FDA Study Population Requirement for BE Studies: Ethics or Science [Regulatives / Guidelines]

posted by jag009  – NJ, 2018-05-18 16:28 (932 d 07:24 ago) – Posting: # 18785
Views: 1,608


» For IND and NDAs, I can understand the need for representative population. But for ANDA submissions for the registration of generics, I wonder why there is need for the use of representative population. Is it based on the need for equity (ethics) or for soundness of data (science)?

Personally I don't see this "representative population" is enforced since many ANDA (and NDA to a certain extent) studies now being conducted in India (as an example) and the study population is basically Indians. In addition, take Indian studies for example, it's very difficult (if not impossible) to get 50-50 or even 40-60 female to male ratios in a study. I have conducted studies India as well and my M/F ratios are usually 80-20 or 90-10 (sometime no females!).

I believe it's a good idea for the study population to be diverse.


Complete thread:

 Admin contact
21,243 posts in 4,431 threads, 1,483 registered users;
online 5 (0 registered, 5 guests [including 4 identified bots]).
Forum time: Saturday 22:53 CET (Europe/Vienna)

I believe there is no philosophical high-road in science,
with epistemological signposts. No, we are in a jungle
and find our way by trial and error,
building our road behind us as we proceed.    Max Born

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz